| 臺大學術典藏 |
2020-05-26T09:27:28Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Chih-Hsin Yang;Chen M.-C;Cheng A.-L;Hsu C.-H;Yeh K.-H;Yu Y.-C;Whang-Peng J;Yang P.-C.; CHIH-HSIN YANG; Chen M.-C; Cheng A.-L; Hsu C.-H; Yeh K.-H; Yu Y.-C; Whang-Peng J; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:26Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Hsu C.-H; Cheng J.C; Wang H.-P; Lee J.-M; Yeh K.-H; CHIH-HSIN YANG; Lin J.-T; Cheng A.-L; Lee Y.-C.; Lin C.-C;Hsu C.-H;Cheng J.C;Wang H.-P;Lee J.-M;Yeh K.-H;Chih-Hsin Yang;Lin J.-T;Cheng A.-L;Lee Y.-C.; Lin C.-C |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C;Yeh K.-H;Chih-Hsin Yang;Hsu C;Tsai Y.-C;Hsu W.-L;Cheng A.-L;Hsu C.-H.; Lin C.-C; Yeh K.-H; CHIH-HSIN YANG; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Lu Y.-S;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Chih-Hsin Yang; Lin C.-C; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L; CHIH-HSIN YANG; Yeh K.-H; Hu F.-C; Chen K.-Y; Shih J.-Y; Lin Z.-Z; Yu C.-J; Cheng A.-L; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F; Chen I.-C; Hsu C; Chang S.-Y; Chien S.-F; Chen Y.-C; Hu F.-C; CHIH-HSIN YANG; Cheng A.-L; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:56Z |
Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
|
Chen L.T.;Chang J.Y;Chiang N.J;Yeh C.G;Wang Y.W;Shen B.N;Cheng A.L;Yeh K.H;Chih-Hsin Yang;Shiah H.S;Chang T.C; Chang T.C; Shiah H.S; CHIH-HSIN YANG; Yeh K.H; Cheng A.L; Shen B.N; Wang Y.W; Yeh C.G; Chiang N.J; Chang J.Y; Chen L.T. |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Cheng A.-L; Hsu C; Yang C.-H; Lu Y.-S; Chia-Chi Lin; Bu C.-F; Yeh K.-H.; Hsu C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Lee J.-M; Yeh K.-H; Yang C.-H; Lin J.-T; Cheng A.-L; Lee Y.-C.; Lee Y.-C.;Cheng A.-L;Lin J.-T;Yang C.-H;Yeh K.-H;Lee J.-M;Wang H.-P;Cheng J.C;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Cheng J.C; Wang H.-P |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Hsu C.-H.;Cheng A.-L;Hsu W.-L;Tsai Y.-C;Hsu C;Yang C.-H;Yeh K.-H;Chia-Chi Lin; Chia-Chi Lin; Yeh K.-H; Yang C.-H; Hsu C; Tsai Y.-C; Hsu W.-L; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:24Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W; Chia-Chi Lin; Huang T.-C; Cheng A.-L; Yeh K.-H; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:20Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C; Huang T.-C; Chia-Chi Lin; Hsieh M.-S; Chang C.-H; Huang P.-M; Lee J.-M; Hsu F.-M; Cheng J.C.-H; Wang H.-P; Yeh K.-H; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C; Chia-Chi Lin; Huang T.-C; Huang P.-M; Kuo H.-Y; Chang C.-H; Wang C.-C; Cheng J.C.-H; Yeh K.-H; Hsu C.-H; Lee J.-M. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
Yang S.-H; Shao Y.-Y; Chia-Chi Lin; Kuo S.-H; Cheng A.-L; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Huang T.-C; Chia-Chi Lin; Wu Y.-C; Chia-Hsien Cheng J; Lee J.-M; Wang H.-P; Huang P.-M; Hsu F.-M; Yeh K.-H; Cheng A.-L; Tzen K.-Y; Hsu C.-H.; Hsu C.-H.;Tzen K.-Y;Cheng A.-L;Yeh K.-H;Hsu F.-M;Huang P.-M;Wang H.-P;Lee J.-M;Chia-Hsien Cheng J;Wu Y.-C;Chia-Chi Lin;Huang T.-C |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine Leiomyosarcoma
|
Cheng A.-L.;Hsiao C.-H;Yen-Shen Lu;Yeh K.-H; Yeh K.-H; YEN-SHEN LU; Hsiao C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.;Wu C.-Y;Chen J.-S;Li C.-C;Liu H.-T;Hsu C.-H;Yen-Shen Lu;Yeh K.-H;Yang C.-H;Shen Y.-C;Hsu C; Hsu C; Shen Y.-C; Yang C.-H; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H;Yen-Shen Lu;Hsu C.-H;Lin J.-F;Hsu C;Kuo S.-H;Li Jr. S;Cheng A.-L.; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Lin J.-F; Hsu C; Kuo S.-H; Li Jr. S; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Yen-Shen Lu;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Yang C.H;Cheng A.L.; Yeh K.H; YEN-SHEN LU; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; Yang C.H; Cheng A.L. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors
|
Kuo M.-L; Kuo S.-H; Cheng A.-L.; Yeh K.-H; Yeh P.-Y; Lien H.-C; YEN-SHEN LU; Yen-Shen Lu;Lien H.-C;Yeh P.-Y;Yeh K.-H;Kuo M.-L;Kuo S.-H;Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:07Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Yen-Shen Lu;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Yang C.-H.; Lin C.-C; Cheng A.-L; Hsu C.-H; YEN-SHEN LU; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:52:00Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H;Hsu C.-H;Chen L.-T;Yen-Shen Lu;Lin C.-H;Yeh P.-Y;Jeng H.-J;Gao M;Yeh K.-H;Cheng A.-L.; Kuo S.-H; Hsu C.-H; Chen L.-T; YEN-SHEN LU; Lin C.-H; Yeh P.-Y; Jeng H.-J; Gao M; Yeh K.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T02:45:35Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C; Huang T.-C; Lin C.-C; Hsieh M.-S; Chang C.-H; Huang P.-M; Lee J.-M; Feng-Ming Hsu; Cheng J.C.-H; Wang H.-P; Yeh K.-H; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-19T01:52:57Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Hsu C.-H.; Cheng A.-L.; Yeh K.-H.; Wang H.-P.; Cheng J.C.-H.; Hsu F.-M.; Lee J.-M.; PEI-MING HUANG; Chang C.-H.; Hsieh M.-S.; Lin C.-C.; Huang T.-C.; Guo J.-C.; Guo J.-C.;Huang T.-C.;Lin C.-C.;Hsieh M.-S.;Chang C.-H.;Pei-Ming Huang;Lee J.-M.;Hsu F.-M.;Cheng J.C.-H.;Wang H.-P.;Yeh K.-H.;Cheng A.-L.;Hsu C.-H. |
| 臺大學術典藏 |
2020-05-19T01:52:54Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C.;Lin C.-C.;Huang T.-C.;Pei-Ming Huang;Kuo H.-Y.;Chang C.-H.;Wang C.-C.;Cheng J.C.-H.;Yeh K.-H.;Hsu C.-H.;Lee J.-M.; Guo J.-C.; Lin C.-C.; Huang T.-C.; PEI-MING HUANG; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; Cheng J.C.-H.; Yeh K.-H.; Hsu C.-H.; Lee J.-M. |
| 臺大學術典藏 |
2020-04-28T07:25:41Z |
Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil
|
Chih-Hung Hsu;Yeh K.-H.;Lui L.T.;Lee Y.-C.;Bu C.-F.;Wang H.-P.;Lin J.-T.;Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Lui L.T.; Lee Y.-C.; Bu C.-F.; Wang H.-P.; Lin J.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:41Z |
Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin
|
Cheng A.-L.; Yeh K.-H.; CHIH-HUNG HSU; Chih-Hung Hsu;Yeh K.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:39Z |
P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
|
Liang J.-T.;Huang K.-C.;Cheng Y.-M.;Hsu H.-C.;Cheng A.-L.;Chih-Hung Hsu;Yeh K.-H.;Wang S.-M.;Chang K.-J.; Liang J.-T.; Huang K.-C.; Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Wang S.-M.; Chang K.-J. |
| 臺大學術典藏 |
2020-04-28T07:25:39Z |
Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Yeh K.-H.;Wang C.-H.;Chih-Hung Hsu;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; CHIH-HUNG HSU; Liu M.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Chih-Hung Hsu;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Yeh K.-H.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection
|
Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Wang S.-M.; Tang C.; Chang K.-J.; Liang J.-T.;Huang K.-C.;Lai H.-S.;Lee P.-H.;Cheng Y.-M.;Hsu H.-C.;Cheng A.-L.;Chih-Hung Hsu;Yeh K.-H.;Wang S.-M.;Tang C.;Chang K.-J.; Liang J.-T.; Huang K.-C.; Lai H.-S.; Lee P.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:36Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.; Chen M.-C.; Cheng A.-L.; CHIH-HUNG HSU; Yeh K.-H.; Yu Y.-C.; Whang-Peng J.; Yang P.-C.; Yang C.-H.;Chen M.-C.;Cheng A.-L.;Chih-Hung Hsu;Yeh K.-H.;Yu Y.-C.;Whang-Peng J.;Yang P.-C. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:34Z |
A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus
|
Pei Y.Y.;Kuo S.-H.;Yeh K.-H.;Chuang S.-E.;Chih-Hung Hsu;Wen C.C.;Lin H.-I.;Gao M.;Cheng A.-L.; Pei Y.Y.; Kuo S.-H.; Yeh K.-H.; Chuang S.-E.; CHIH-HUNG HSU; Wen C.C.; Lin H.-I.; Gao M.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:31Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
CHIH-HUNG HSU;Cheng A.-L.;Hsu W.-L.;Tsai Y.-C.;Hsu C.;Yang C.-H.;Yeh K.-H.;Lin C.-C.; Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2020-04-28T07:25:26Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.; CHIH-HUNG HSU; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. ;Chih-Hung Hsu ;Chen L.-T. ;Lu Y.-S. ;Lin C.-H. ;Yeh P.-Y. ;Jeng H.-J. ;Gao M. ;Yeh K.-H. ;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H. ;Cheng A.-L. ;Lin C.-W. ;Chih-Hung Hsu ;Wu M.-S. ;Yeh K.-H. ;Tzeng Y.-S. ;Chen L.-T.; Kuo S.-H.; Cheng A.-L.; Lin C.-W.; CHIH-HUNG HSU; Wu M.-S.; Yeh K.-H.; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:17Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Hsieh M.-S.; Chang C.-H.; Huang P.-M.; Lee J.-M.; Hsu F.-M.; Cheng J.C.-H.; Wang H.-P.; Yeh K.-H.; Cheng A.-L.; CHIH-HUNG HSU; Lin C.-C.; Huang T.-C.; Guo J.-C.; Guo J.-C.;Huang T.-C.;Lin C.-C.;Hsieh M.-S.;Chang C.-H.;Huang P.-M.;Lee J.-M.;Hsu F.-M.;Cheng J.C.-H.;Wang H.-P.;Yeh K.-H.;Cheng A.-L.;Chih-Hung Hsu |
| 臺大學術典藏 |
2020-04-28T07:25:12Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
CHIH-HUNG HSU; Yeh K.-H.; Lin C.-C.; Huang T.-C.; Huang P.-M.; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; Cheng J.C.-H.; Guo J.-C.; Guo J.-C.;Lin C.-C.;Huang T.-C.;Huang P.-M.;Kuo H.-Y.;Chang C.-H.;Wang C.-C.;Cheng J.C.-H.;Yeh K.-H.;Chih-Hung Hsu;Lee J.-M.; Lee J.-M. |
| 臺大學術典藏 |
2020-04-28T07:25:11Z |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
|
Chia-Hsien Cheng J.; Lee J.-M.; Wang H.-P.; Huang P.-M.; Hsu F.-M.; Yeh K.-H.; Cheng A.-L.; Tzen K.-Y.; CHIH-HUNG HSU; Lin C.-C.; Wu Y.-C.; Huang T.-C.; Huang T.-C.;Lin C.-C.;Wu Y.-C.;Chia-Hsien Cheng J.;Lee J.-M.;Wang H.-P.;Huang P.-M.;Hsu F.-M.;Yeh K.-H.;Cheng A.-L.;Tzen K.-Y.;Chih-Hung Hsu |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy
|
Guo J.-C.;Lin C.-C.;Huang T.-C.;Huang P.-M.;Kuo H.-Y.;Chang C.-H.;Wang C.-C.;Chia-Hsien Cheng;Yeh K.-H.;Hsu C.-H.;Lee J.-M.; Guo J.-C.; Lin C.-C.; Huang T.-C.; Huang P.-M.; Kuo H.-Y.; Chang C.-H.; Wang C.-C.; CHIA-HSIEN CHENG; Yeh K.-H.; Hsu C.-H.; Lee J.-M. |
| 臺大學術典藏 |
2020-04-10T12:51:32Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Liu M.-Y.;Chiun Hsu;Lin J.-T.;Yeh K.-H.;Cheng A.-L.; Cheng A.-L.; Yeh K.-H.; Lin J.-T.; Chiun Hsu; Liu M.-Y. |
